We are live on ! Find out more
IMRX icon

Immuneering
IMRX

51 hedge funds and large institutions have $34.3M invested in Immuneering in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less funds holding

Funds holding: 52 → 51 (-1)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

14.76% less ownership

Funds ownership: 55.3% → 40.54% (-15%)

42% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 24

71% less capital invested

Capital invested by funds: $119M → $34.3M (-$84.7M)

Holders
51
Holders Change
-1
Holders Change %
-1.92%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
14
Reduced
24
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$728K
2
ETC
Exchange Traded Concepts
Oklahoma
+$453K
3
BCM
Bridgeway Capital Management
Texas
+$420K
4
SM
Southport Management
Wyoming
+$364K
5
Millennium Management
Millennium Management
New York
+$290K

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$13.8M
2
CAM
Cormorant Asset Management
Massachusetts
-$5.09M
3
BlackRock
BlackRock
New York
-$4.04M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.44M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$9.52M -$5.09M -909,091 -22%
Citadel Advisors
2
Citadel Advisors
Florida
$5.44M -$1.1M -195,892 -9%
BlackRock
3
BlackRock
New York
$3.98M -$4.04M -720,286 -34%
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.48M +$728K +129,851 +12%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$2.63M -$13.8M -2,467,834 -73%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$1.34M +$102K +18,287 +4%
Goldman Sachs
7
Goldman Sachs
New York
$1.31M -$15.8K -2,826 -0.6%
State Street
8
State Street
Massachusetts
$1.09M +$18.1K +3,234 +0.9%
HS
9
HighVista Strategies
Massachusetts
$736K – – –
Fidelity Investments
10
Fidelity Investments
Massachusetts
$674K -$1.44M -256,249 -52%
Northern Trust
11
Northern Trust
Illinois
$509K -$44.4K -7,922 -4%
TD Asset Management
12
TD Asset Management
Ontario, Canada
$436K -$263K -47,000 -24%
BCM
13
Bridgeway Capital Management
Texas
$330K +$420K +75,000 +192%
ETC
14
Exchange Traded Concepts
Oklahoma
$284K +$453K +80,838 +464%
SM
15
Southport Management
Wyoming
$260K +$364K +65,000 +259%
Manulife (Manufacturers Life Insurance)
16
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$252K -$21.6K -3,858 -4%
Millennium Management
17
Millennium Management
New York
$183K +$290K +51,824 +453%
Charles Schwab
18
Charles Schwab
California
$175K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$155K -$57.4K -10,251 -16%
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
$145K -$280K -50,000 -50%
Morgan Stanley
21
Morgan Stanley
New York
$132K -$374K -66,677 -59%
N
22
Nuveen
North Carolina
$127K – – –
Corient Private Wealth
23
Corient Private Wealth
Florida
$125K +$78.4K +14,000 +48%
First Manhattan
24
First Manhattan
New York
$96.1K +$186K +33,250 New
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$90.6K +$82.2K +14,665 +88%
1
2 3

IMRX Hedge Fund Activity: Q1 2024 in Review

51 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q1 2024, worth a combined $34.3M — down 71% from $119M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of IMRX and 7 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 14 added.

The largest buyer was Vanguard Group, adding an estimated $728K. The largest seller was T. Rowe Price Associates, cutting an estimated $13.8M.

  • 51 institutional investors held Immuneering (IMRX) as of Q1 2024, down from 52 in Q4 2023.
  • Funds reported $34.3M of Immuneering stock for Q1 2024, down 71% quarter-over-quarter.
  • 7 funds opened new Immuneering positions in Q1 2024 and 8 closed out, a net change of -1 holder.
  • The largest Immuneering buyer in Q1 2024 was Vanguard Group, an estimated $728K added.
  • The largest Immuneering seller in Q1 2024 was T. Rowe Price Associates, an estimated $13.8M sold.

Based on aggregated 13F filings for Q1 2024.